Moderating Orders Signal Improved Outlook for IDEX in Health and Science Segment

The article discusses IDEX's Q1 FY24 results, highlighting a 6% drop in organic revenue and a 1% decline in orders, with the Health & Science Technologies segment facing particular challenges. However, there is a positive indication of order moderation, suggesting a potential recovery in end-markets and a reduction in inventory destocking. The Fluid & Metering Technologies and Fire & Safety/Diversified Products segments also experienced varying levels of growth or recovery. The article concludes with a 'Buy' rating and a fair price target of $220 per share.

IDEX Corporation (NYSE: IEX), a leading global fluid and metering technologies company, recently reported its financial results for the first quarter of FY24. Although the company experienced a 6% decline in organic revenue and a 1% drop in orders, there are positive signs of order moderation and varying levels of growth or recovery in specific segments [1].

First Quarter Performance

IDEX reported net sales of $800.5 million, down from $845.4 million in the same period last year. Organic net sales dropped by 6%, and the company's gross profit decreased by 25.1% to $357.4 million. However, the company's adjusted gross profit, which excludes restructuring and asset impairment charges, only declined by 22.6% to $359.9 million. This discrepancy demonstrates IDEX's ability to maintain a relatively stable gross margin despite the overall decline in sales.

Segment Analysis

The Health & Science Technologies segment experienced the most significant challenges, contributing to the overall decline in organic net sales. However, the Fluid & Metering Technologies and Fire & Safety/Diversified Products segments showed varying degrees of growth or recovery. In the Fluid & Metering Technologies segment, which accounts for the majority of IDEX's revenue, organic net sales declined by 4.3%, but the adjusted gross profit increased by 1.9%. In contrast, the Fire & Safety/Diversified Products segment reported a 3.3% increase in organic net sales, and the adjusted gross profit grew by 16.2%.

Order Trends and Outlook

IDEX experienced an encouraging lift in sequential orders from its core industrial and municipal markets, indicating a potential reduction in inventory destocking. The company also noted differing rates of recovery within the Health & Science Technologies segment's targeted markets. Eric D. Ashleman, IDEX Corporation's CEO and President, expressed commitment to deploying resources to build momentum in these advantaged markets through the remainder of the year [1].

Financial Outlook

For the full year, IDEX projects organic sales growth to be 0% to 2% over the prior year. The company expects full-year GAAP diluted EPS to be $7.13-$7.43, and adjusted diluted EPS to be $8.15-$8.45. Second quarter organic sales are projected to decline 2% to 3% over the prior year period, with GAAP diluted EPS projected to be $1.75-$1.80 and adjusted diluted EPS projected to be $2.00-$2.05 [1].

Conclusion

Although IDEX reported a 6% decline in organic revenue and a 1% drop in orders in the first quarter of FY24, there are positive signs of order moderation and varying levels of growth or recovery in specific segments. With a commitment to deploying resources to build momentum in advantaged markets, IDEX remains optimistic about its prospects for the remainder of the year.

References:
[1] IDEX Corporation. (2024, April 23). IDEX Reports First Quarter Results and Confirms Full Year. Business Wire. https://www.businesswire.com/news/home/20240423005232/en/